PolarityTE Revenue and Competitors
Estimated Revenue & Valuation
- PolarityTE's estimated annual revenue is currently $1.6M per year.
- PolarityTE received $17.8M in venture funding in September 2017.
- PolarityTE's estimated revenue per employee is $47,364
- PolarityTE's total funding is $17.8M.
Employee Data
- PolarityTE has 33 Employees.
- PolarityTE grew their employee count by -48% last year.
PolarityTE's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Director, Executive Programs | Reveal Email/Phone |
2 | Clinical Trial Manager | Reveal Email/Phone |
3 | Manufacturing Technician II | Reveal Email/Phone |
PolarityTE Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 5 | -17% | N/A | N/A |
#2 | $1.4M | 9 | -10% | N/A | N/A |
#3 | $5.9M | 38 | 41% | N/A | N/A |
#4 | $1.1M | 7 | -53% | N/A | N/A |
#5 | $1.6M | 10 | 11% | N/A | N/A |
#6 | $21.2M | 137 | 10% | N/A | N/A |
#7 | $1.6M | 33 | -48% | $17.8M | N/A |
#8 | $1.9M | 12 | 0% | N/A | N/A |
#9 | $3.7M | 24 | 9% | N/A | N/A |
#10 | $0.9M | 6 | 0% | N/A | N/A |
What Is PolarityTE?
PolarityTE (NASDAQ: COOL) is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.
keywords:N/A$17.8M
Total Funding
33
Number of Employees
$1.6M
Revenue (est)
-48%
Employee Growth %
N/A
Valuation
N/A
Accelerator
PolarityTE News
Equities research analysts expect that PolarityTE, Inc. (NASDAQ:PTE Get Rating) will report ($0.08) earnings per share (EPS) for the...
Thinking about buying stock in Polarityte, RLX Technology, Bitnile, Aterian, or Cyclacel Pharmaceuticals? InvestorsObserver (PRNewsfoto/...
PolarityTE, Inc. (NASDAQ:PTE) Q4 2021 Earnings Conference Call March 30, 2022 8:30 AM ET. Company Participants.
SALT LAKE CITY, Sept. 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing ...
SALT LAKE CITY, Aug. 28, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4M | 33 | 0% | N/A |
#2 | $3.8M | 33 | 43% | N/A |
#3 | $6M | 33 | -13% | N/A |
#4 | $8.7M | 33 | 0% | N/A |
#5 | $3.8M | 33 | 3% | N/A |
PolarityTE Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2017-09-22 | $17.8M | Undisclosed | Cantor Fitzgerald | Article |